Momentum of Current Clinical Trial Recruitment Continues; Clinical Trial Pipeline for Severe Heart Failure Patients Expanding

Adult Stem Cell Patient Treatments Progress in U.S. Phase II Cardiac and Vascular Regeneration Clinical Trials; Patient Enrollment On Track With Guidance

Industry Veteran and Aastrom Board Member, Tim Mayleben, to Become New CEO in December 2009; Expected That George Dunbar, Current CEO, Will Become Chairman of the Board; Transitions to Strengthen and Expand Senior Management Team to Become Effective Immediately After Company's Annual Meeting Currently Set for December 14, 2009

Results From Three Patient Treatments Involving Investigational Stem Cell Therapy Developed by Aastrom Biosciences Presented During the 2nd Annual Congress of Regenerative Medicine & Stem Cell in Dalian, China

ANN ARBOR, Mich., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, and Elmar Burchardt, MD,

Aastrom Has Until October 1, 2009 to Regain Compliance

Patient Death Unrelated to Aastrom's CRCs; Trial to Resume At All Clinical Sites for Patients Suffering From Dilated Cardiomyopathy

Treatment Patient Released From Hospital Later Dies; Investigation Underway to Determine Cause of Death

ANN ARBOR, Mich., May 8, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported financial results for the third fiscal quarter ended March 31, 2009.

Encouraging Early Data Reported in Severe Heart Failure Patients With Dilated Cardiomyopathy